Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904790 | 0.85 | GRM5 (0.45) | HPGDGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9900912 | 0.82 | GRM5 (0.41) | HPGDGRM5CYP1A2 | |
| SCHEMBL9900649 | 0.81 | GRM5 (0.41) | HPGDGRM5SMN1; SMN2 | |
| SCHEMBL877979 | 0.66 | RAB9A (0.32) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL9900971 | 0.65 | GRM5 (0.45) | HPGDGRM5MEN1KMT2ANPC1 | |
| SCHEMBL9937521 | 0.63 | GRM5 (0.46) | GRM5CYP1A2 | |
| SCHEMBL5100085 | 0.62 | EGLN1 (0.52) | HPGD | |
| SCHEMBL5813321 | 0.62 | SMYD3 (0.57) | KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6335179 | 0.62 | L3MBTL1 (0.55) | SMN1; SMN2 | |
| SCHEMBL6419868 | 0.61 | LMNA (0.51) | HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255103-B2 | Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators | VANDERBILT UNIVERSITY (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2014-07-31 | — | — | US | disclosed |
| US-8703946-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2648723-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2012-11-22 | — | — | US | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | HPGD 3380/4885GRM5 1/4885MEN1 4679/4885 |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | HPGD 3380/4885GRM5 1/4885MEN1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.